TCOV
NTLA icon

Trust Company of Vermont’s Intellia Therapeutics NTLA Stock Holding History

Trust Company of Vermont’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-216
Closed -$4.83K – 1095
2024
Q2 		$4.83K Buy
+216
New +$5.14K ﹤0.01% 755

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trust Company of Vermont's NTLA Position: Q3 2024 in Review

Trust Company of Vermont sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 216 shares — an estimated $4.83K sold.

Trust Company of Vermont first reported a position in NTLA in Q2 2024 and held it in 1 quarter. The position peaked at $4.83K in Q2 2024. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Trust Company of Vermont reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Trust Company of Vermont sold 216 Intellia Therapeutics shares in Q3 2024, an estimated $4.83K.
  • Trust Company of Vermont first reported a position in Intellia Therapeutics in Q2 2024 and held it in 1 quarter.
  • Trust Company of Vermont's Intellia Therapeutics position peaked at $4.83K in Q2 2024.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Trust Company of Vermont's 13F filing for Q3 2024, filed 16 Oct 2024.